AmerisourceBergen Coughs Up $625M to Resolve U.S. Government Probe Post author:Sam Post published:November 21, 2017 Post category:BioPharma The agreement, whose final terms are still being negotiated, must be approved by a court. Source: BioSpace You Might Also Like FDA Grants Yisheng Biopharma's Clinical Treatment its Second Orphan Drug Designation February 25, 2018 Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active… December 14, 2017 biOasis Announces Voting Results For 2017 Annual Meeting September 21, 2017
FDA Grants Yisheng Biopharma's Clinical Treatment its Second Orphan Drug Designation February 25, 2018
Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active… December 14, 2017